See more : Mega Lifesciences Public Company Limited (MEGA.BK) Income Statement Analysis – Financial Results
Complete financial analysis of IVD Medical Holding Limited (1931.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IVD Medical Holding Limited, a leading company in the Medical – Distribution industry within the Healthcare sector.
- Superland Group Holdings Limited (0368.HK) Income Statement Analysis – Financial Results
- Ador Fontech Limited (ADORFO.BO) Income Statement Analysis – Financial Results
- Rediff.com India Limited (REDFY) Income Statement Analysis – Financial Results
- CCSC Technology International Holdings Limited Ordinary Shares (CCTG) Income Statement Analysis – Financial Results
- Vection Technologies Limited (VR1.AX) Income Statement Analysis – Financial Results
IVD Medical Holding Limited (1931.HK)
About IVD Medical Holding Limited
IVD Medical Holding Limited, an investment holding company, distributes In vitro diagnostic (IVD) products in Mainland China and internationally. The company operates through three segments: Distribution Business, Maintenance Services, and Self-branded Products Business. It offers IVD analysers, reagents, and other consumables for various IVD testing categories, including hematology and body fluid, immunoassay, clinical chemistry, molecular, microbiology, and point-of-care testing. The company also provides haemostasis products; solution services to the clinical laboratories of hospitals; and maintenance services, such as maintenance and repair, installation, and end customer training services. In addition, it researches, develops, manufactures, and sells IVD analyzers and reagents under the IVD brand. The company offers its products to hospitals and healthcare institutions, logistics providers, and distributors. IVD Medical Holding Limited was founded in 1993 and is headquartered in Shanghai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.09B | 2.75B | 2.73B | 2.43B | 2.33B | 413.64M | 338.27M | 290.44M |
| Cost of Revenue | 2.42B | 2.14B | 2.16B | 1.95B | 1.83B | 296.96M | 230.05M | 206.54M |
| Gross Profit | 671.70M | 608.14M | 566.27M | 476.17M | 503.20M | 116.67M | 108.21M | 83.90M |
| Gross Profit Ratio | 21.75% | 22.12% | 20.74% | 19.61% | 21.57% | 28.21% | 31.99% | 28.89% |
| Research & Development | 8.67M | 7.22M | 7.27M | 3.52M | 2.74M | 716.00K | 597.00K | 117.00K |
| General & Administrative | 159.98M | 152.92M | 183.85M | 144.09M | 124.68M | 54.70M | 9.20M | 13.16M |
| Selling & Marketing | 136.31M | 117.24M | 122.57M | 105.68M | 96.62M | 11.63M | 10.31M | 11.68M |
| SG&A | 296.29M | 272.85M | 307.22M | 249.10M | 221.59M | 68.66M | 19.51M | 24.84M |
| Other Expenses | 0.00 | -37.50M | -17.48M | -1.56M | -111.48M | 0.00 | 2.09M | -45.00K |
| Operating Expenses | 304.00M | 295.74M | 279.66M | 222.57M | 202.73M | 574.00K | 57.10M | 52.32M |
| Cost & Expenses | 2.72B | 2.44B | 2.44B | 2.17B | 2.03B | 297.54M | 287.15M | 258.86M |
| Interest Income | 2.91M | 28.61M | 18.66M | 21.64M | 3.53M | 1.53M | 1.65M | 412.00K |
| Interest Expense | 21.04M | 30.58M | 20.42M | 23.75M | 7.78M | 0.00 | 0.00 | 98.00K |
| Depreciation & Amortization | 37.56M | 35.29M | 38.81M | 37.76M | 49.44M | 17.75M | 14.66M | 10.80M |
| EBITDA | 397.93M | 349.66M | 286.17M | 250.05M | 318.80M | 65.75M | 67.54M | 77.49M |
| EBITDA Ratio | 12.88% | 13.02% | 10.48% | 10.30% | 13.67% | 15.90% | 41.42% | 26.74% |
| Operating Income | 367.70M | 335.29M | 259.05M | 227.06M | 281.61M | 48.01M | 125.46M | 66.85M |
| Operating Income Ratio | 11.91% | 12.20% | 9.49% | 9.35% | 12.07% | 11.61% | 37.09% | 23.02% |
| Total Other Income/Expenses | -28.37M | -43.99M | 16.16M | 8.41M | 15.33M | 69.61M | 2.86M | 34.48M |
| Income Before Tax | 339.33M | 283.79M | 267.94M | 231.96M | 296.94M | 117.62M | 128.32M | 66.06M |
| Income Before Tax Ratio | 10.99% | 10.32% | 9.81% | 9.55% | 12.73% | 28.44% | 37.93% | 22.74% |
| Income Tax Expense | 102.20M | 88.26M | 106.19M | 77.34M | 42.12M | 18.11M | 15.72M | 8.89M |
| Net Income | 238.16M | 210.00M | 174.54M | 158.72M | 275.00M | 103.44M | 110.74M | 56.27M |
| Net Income Ratio | 7.71% | 7.64% | 6.39% | 6.54% | 11.79% | 25.01% | 32.74% | 19.37% |
| EPS | 0.18 | 0.16 | 0.13 | 0.12 | 0.24 | 0.17 | 0.08 | 0.04 |
| EPS Diluted | 0.18 | 0.16 | 0.13 | 0.12 | 0.21 | 0.17 | 0.08 | 0.04 |
| Weighted Avg Shares Out | 1.35B | 1.34B | 1.32B | 1.33B | 1.13B | 617.65M | 1.33B | 1.33B |
| Weighted Avg Shares Out (Dil) | 1.35B | 1.35B | 1.35B | 1.34B | 1.14B | 617.64M | 1.33B | 1.33B |
Source: https://incomestatements.info
Category: Stock Reports